Brief: Jacobio Pharmaceuticals Group Receives U.S. FDA Investigational New Drug Clearance
03/05/2021 07:32
May 3 (Reuters) - Jacobio Pharmaceuticals Group Co Ltd
1167.HK :
* RECEIVES US FDA INVESTIGATIONAL NEW DRUG CLEARANCE FOR
KRAS G12C
INHIBITOR
Source text for Eikon: urn:newsml:reuters.com:*:nPn7TMJ9ka
Further company coverage: 1167.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Jacobio Pharmaceuticals
See all newsBrief: Jacobio Pharmaceuticals Appoints Xiaojie Wang As Vice Chairperson
China's Jacobio Pharmaceuticals H1 revenue jumps on licensing boost
Brief: Jacobio Pharmaceuticals Group Posts H1 Net Income Attributable RMB 600.6 Million
Brief: Jacobio Pharmaceuticals Expects HY Net Profit Of Not Less Than RMB600 Million
HK-listed Jacobio Pharmaceuticals climbs on share buyback plan